Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Heart, Heart Failure With Preserved Ejection Fraction (HFPEF)
- Main trialPhase 1
- “A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)”In the company’s words, NCT07219511 on ClinicalTrials.gov
Other drugs for Heart Failure With Preserved Ejection Fraction (HFPEF)
- Balcinrenone/dapagliflozinAstraZeneca · Phase 3
- DapagliflozinAstraZeneca · Phase 3
- HiCM-188HELP Therapeutics Co., Ltd. · Phase 3
- Omecamtiv mecarbilCytokinetics · Phase 3
- InclisiranNovartis · Phase 3
- EmpagliflozinBoehringer Ingelheim · Phase 3
Coming up1
- NovPhase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | Nov 2026 | A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026